HaVOC: haloperidol versus ondansetron for cannabis hyperemesis syndrome
Cannabis Use Disorder
Enrolment: 33 · Results not recorded
Loading the evidence…
Drug · Serotonin 2a (5-HT2a) receptor antagonist (ANTAGONIST) and D2-like dopamine receptor inverse agonist (INVERSE AGONIST); both direct interactions with disease efficacy true.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cannabis Use Disorder
Enrolment: 33 · Results not recorded
Schizophrenia, First-Episode
Enrolment: 300 · Results not recorded
Delirium · Impaired Cognition
Enrolment: 566 · Results not recorded
Psychotic Disorders · Aggression
Enrolment: 300 · Results not recorded
Bipolar Disorder · Manic Disorder
Enrolment: 439 · Results not recorded
Delirium · Cognitive Impairment
Enrolment: 551 · Results not recorded
Postoperative Nausea and Vomiting
Enrolment: 40 · Results not recorded
Healthy volunteers
Enrolment: 11 · Results not recorded
Normal Volunteers
Enrolment: 80 · Results not recorded
Movement Disorders · Lactic Acidosis
Enrolment: 60 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Controlled cortical impact (6 mm flat tip, 2.8 mm tissue deformation at 4 m/s, right hemisphere craniectomy)
No overall differences between injured treatment groups on beam balance or beam walk across days 1-5, and all injured groups were impaired relative to sham. On the final beam-walk day the continuous haloperidol group took significantly longer to traverse the beam than all other injured groups. In t…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.